QUINCE THERAPEUTICS INC (QNCX) Stock Price, Forecast & Analysis
NASDAQ:QNCX • US22053A1079
QNCX Key Statistics, Chart & Performance
The current stock price of QNCX is 0.1501 USD. In the past month the price decreased by -95.37%. In the past year, price decreased by -89.28%.
QNCX Technical Analysis
QNCX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QNCX. While QNCX seems to be doing ok healthwise, there are quite some concerns on its profitability.
QNCX Financial Highlights
Over the last trailing twelve months QNCX reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 2.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.85% | ||
| ROE | -5380.45% | ||
| Debt/Equity | 0 |
QNCX Forecast & Estimates
11 analysts have analysed QNCX and the average price target is 6.12 USD. This implies a price increase of 3977.28% is expected in the next year compared to the current price of 0.1501.
QNCX Ownership
QNCX Latest News, Press Relases and Analysis
QNCX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About QNCX
Company Profile
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Company Info
QUINCE THERAPEUTICS INC
601 Gateway Boulevard, Suite 1250
South San Francisco CALIFORNIA US
Employees: 36
Phone: 14159105717
QUINCE THERAPEUTICS INC / QNCX FAQ
Can you describe the business of QUINCE THERAPEUTICS INC?
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
What is the current price of QNCX stock?
The current stock price of QNCX is 0.1501 USD. The price decreased by -7.46% in the last trading session.
Does QNCX stock pay dividends?
QNCX does not pay a dividend.
How is the ChartMill rating for QUINCE THERAPEUTICS INC?
QNCX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for QNCX stock?
11 analysts have analysed QNCX and the average price target is 6.12 USD. This implies a price increase of 3977.28% is expected in the next year compared to the current price of 0.1501.
Should I buy QNCX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QNCX.